Mosqueda GJL, Mata MJA, Navarro ÁS, Torres RD, García AMC, Reyes FLF, Olivares AN

Language: Spanish
References: 19
Page: 53-58
PDF size: 197.25 Kb.

ABSTRACT

Background. The ultimate goal of treatment in patients with HIV is reduce the viral load to a minimum and increase the CD4 cells in order to achieve the undetectability. Increased life expectancy resulting from effective antiretroviral therapy for human immunodeficiency virus (HIV)–1 is now associated with increased comorbidities, including renal function alteration with some antiretroviral therapies.
Material and method. The real-world MexHIV study aims to assess the durability of treatment with boosted Darunavir (DRV) ethanolate 800 mg in Mexican HIV-1 patients. Eligible patients were treatment-naïve or treatment-experienced (virologically suppressed or failing). This interim analysis describes sociodemographic and renal findings of those patients treated with Cobicistat- boosted DRV ethanolate–containing regimens. Sociodemographic and renal findings, including serum creatinine (SCr) and estimated glomerular filtration rate (eGFR), were assessed at baseline and visit 1 (3 months). Analysis of renal parameters focused on patients with available paired SCr and eGFR measurements. Safety was assessed throughout the study.
Results. Of 164 patients who met the study inclusion criteria, 157 were included in this interim analysis (32 in the renal parameter analysis). The majority of patients (84.1%) were male and mean±SD age was 40.6±10.4 years. Mean±SD SCr level increased from 0.86±0.16 mg/dL (baseline) to 0.89±0.16 mg/dL (visit 1). Mean±SD eGFR decreased from 111.8±30.9 mL/min (baseline) to 101.1±19.2 mL/min (visit 1). No serious AEs were reported.
Conclusions. Findings support clinical guidelines recommending cobicistat-boosted DRV ethanolate–containing regimens as a strong treatment option for patients with HIV-1.

REFERENCES

1. Government of Mexico, Guide to antiretroviral management of people with HIV. Available at: https://www. gob.mx/cms/uploads/attachment/file/470115/Fragmento_ Gu_a_de_Manejo_ARV.pdf.

2. Jarrin I, Hernandez-Novoa B, Alejos B, et al., “Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010”, Antivir Ther, 2013, 18 (2): 161-170.

3. Guaraldi G, Orlando G, Zona S, et al., “Premature age-related comorbidities among HIV-infected persons compared with the general population”, Clin Infect Dis, 2011, 53 (11): 1120-1126.

4. Bagnis CI, Stellbrink HJ, “Protease inhibitors and renal function in patients with HIV infection: a systematic review”, Infect Dis Ther, 2015, 4: 15–50.

5. Schmid S, Opravil M, Moddel M, et al., “Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies”, Virchows Arch, 2007, 450 (6): 665-670.

6. Brewster UC, Perazella MA, “Acute interstitial nephritis associated with atazanavir, a new protease inhibitor”, Am J Kidney Dis, 2004, 44 (5): e81-84.

7. Inagaki I, Adachi M, Ito H, et al., “Atazanavir-induced urine crystals demonstrated by infrared spectroscopic analysis”, Urol Int, 2015, 94 (1): 121-124.

8. Pacanowski J, Poirier JM, Petit I, Meynard JL, Girard PM, “Atazanavir urinary stones in an HIV-infected patient”, AIDS, 2006, 20 (16): 2131.

9. Chughlay MF, Njuguna C, Cohen K, Maartens G, “Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis”, AIDS, 2015, 29 (4): 503-504.

10. Doco-Lecompte T, Garrec A, Thomas L, et al., “Lopinavir- ritonavir (Kaletra) and lithiasis: seven cases”, AIDS, 2004, 18 (4): 705-706.

11. Shafi T, Choi MJ, Racusen LC, et al., “Ritonavir-induced acute kidney injury: kidney biopsy findings and review of literature”, Clin Nephrol, 2011, 75 Suppl 1: 60-64.

12. Scherzer R, Estrella M, Li Y, et al., “Association of tenofovir exposure with kidney disease risk in HIV infection”, AIDS, 2012, 26 (7): 867-875.

13. Jose S, Nelson M, Phillips A, et al., “Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir”, AIDS, 2017, 31 (4): 485-492.

14. German P, Liu HC, Szwarcberg J, et al., “Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function”, J Acquir Immune Defic Syndr, 2012, 61 (1): 32-40.

15. Levey AS, Stevens LA, Schmid CH, et al., “A new equation to estimate glomerular filtration rate”, Ann Intern Med, 2009, 150 (9): 604-612.

16. Levin A, Stevens PE, Bilous RW, et al., “Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease”, Kidney International Supplements, 2013, 3 (1): 1-150.

17. Tashima K, Crofoot G, Tomaka FL, et al., “Cobicistat- boosted darunavir in HIV-1-infected adults: week 48 results of a phase IIIb, open-label single-arm trial”, AIDS Research and Therapy, 2014, 11 (39).

18. PREZCOBIX® (darunavir and cobicistat) [package insert]. Titusville, NJ: Janssen Therapeutics; June 2018.

19. Capetti A, Cossu MV, Rizzardini G, “Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance”, Expert Opin Pharmacother, 2015, 16 (17): 2689-2702.